
Exhibit 10.1

{E158 Redactions} with respect to certain portions hereof  {E1 denoted}  with "***"

COLLABORATION AGREEMENT

This Collaboration Agreement (the "Agreement") is  {E2 made}  as of  April 14th, 2020  (the "Effective  Date  ") by and between Anixa Biosciences, Inc., a Delaware corporation,  {E3 located}  at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A. ("Anixa"), and OntoChem GmbH, a German limited liability company,  {E4 located}  at BlÃ¼cherstr. 24, D-06120 Halle (Saale), Germany ("OntoChem"). Anixa and OntoChem are  {E5 referred}  to herein individually as a "Party" and collectively as the "Parties."

WHEREAS, the Parties  {E6 wish}  to  {E7 collaborate}  in the {E159 discovery} and {E160 development} of novel drug candidates for the {E161 treatment} of COVID-19 in accordance with the terms and conditions of this Agreement. NOW, THEREFORE, in consideration of the premises and the mutual promises set forth in this Agreement, and other good and valuable consideration, the {E162 receipt} and sufficiency of which are hereby  {E8 acknowledged}  , the Parties  {E9 agree}  as  follows  :

1.  {E10 Defined}  Terms. 1.1 "Affiliate" means, with respect to a Party, any entity directly or indirectly controlled by, controlling or under common control with such Party. For purposes of this definition, "control" means (a) ownership of fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity or investor in a particular jurisdiction) or more of the outstanding voting stock or other ownership interest of an entity, or (b) possession of the power to (i) elect, appoint, direct or remove fifty percent (50%) or more of the members of the board of directors or other governing body of an entity or (ii) otherwise direct or cause the direction of the {E163 management} or policies of an entity by contract or otherwise. 1.2 "Hit Compound" means any chemical entity that is determined in performing the Research Plan to meet the Hit Criteria. 1.3 "Hit Criteria" means the criteria identified as "Hit Criteria" as set forth in the Research Plan. 1.4 "{E164 Invention}" means any {E165 invention}, know-how, data, {E166 discovery} or proprietary information, whether or not patentable, that is made or generated solely by the Representatives of Anixa or OntoChem or jointly by the Representatives of Anixa and OntoChem in performing the Research Plan, including all intellectual property rights in the foregoing. 1.5 "Representative" means, with respect to a Party, an officer, director, employee, agent or permitted subcontractor of such Party. 1.6 "Research Plan" means the research plan attached hereto as Exhibit A. 1





1.7 "SAR" means the relationship between the chemical or three-dimensional structure of a compound and its biological activity, and includes the {E167 determination} of the chemical groups responsible for evoking a target biological {E168 effect}. 1.8 "Target" means: (a) any protease of any coronavirus, including Mpro; (b) the Nsp15-pRB ribonuclease protein- protein {E169 interaction}; (c) all mutants and variants of any molecule or component referenced in clauses (a) or (b); and (d) all truncated forms (including fragments) of any molecule or component referenced in clauses (a) or (b) or mutant or variant referenced in clause (c). 1.9 "Variant" means, with respect to any Hit Compound: (a) all compounds within the genus of compounds to which such Hit Compound would belong under United States patent laws as referenced in the Selection Notice (as defined below); and (b) any base form, metabolite, ester, salt form, racemate, stereoisomer, polymorph, hydrate, anhydride or solvate of such Hit Compound or any other compound described in clause (a) (in the case of this clause (b), without regard to whether such compound is referenced in the Selection Notice). 2. Research Program. 2.1 Performance. The Parties will diligently  {E11 perform}  their respective {E171 activities} set forth in the Research Plan (such {E171 activities}, collectively, the "Research {E171 Program}") in accordance with the timelines set forth therein, with the objective of  {E12 identifying}  Hit Compounds and Lead Scaffolds that  {E13 modulate}  the applicable Target. Without  {E14 limiting}  the foregoing, OntoChem will (a)  {E15 provide}  all deliverables set forth in the Research Plan (each, a "Deliverable") and (b)  {E16 obtain}  any {E173 authorizations}, {E174 approvals} and licenses  {E17 required}  for {E175 performance} of the Research Plan. If any terms set forth in the Research Plan conflict with the terms set forth in this Agreement, the terms of this Agreement will  {E18 control}  unless expressly  {E19 indicated}  to the contrary in the Research Plan. The Research Plan may not be  {E20 amended}  without the prior  {E21 written}  consent of both Parties. If, from time to time, the Parties  {E22 desire}  to  {E25 expand}  the scope of the Research Program, then they will  {E24 negotiate}  in good faith a potential {E177 amendment} of the Research Plan in regard to such  {E25 expanded}  scope, on commercially reasonable terms, but neither Party will be  {E26 obligated}  to  {E27 enter}  into any such {E177 amendment}. 2.2 Weekly Updates. OntoChem will  {E28 provide}  Anixa with  weekly  (or more frequently as  {E29 requested}  ) {E179 updates}  {E30 regarding}  its {E180 progress} under the Research {E181 Program} via teleconference, videoconference or e-mail, and the Parties will  {E31 make}  appropriate personnel available in a timely manner to  {E32 discuss}  and  {E33 provide}  {E182 feedback} in regard to such {E183 updates}. 2.3 Delivery of Data. In conjunction with each  weekly  update  {E34 described}  in Section 2.2, OntoChem will  {E35 deliver}  to Anixa all data  {E36 generated}  under the Research Plan since the  {E37 preceding}  {E184 update}. In addition, Anixa will have the right to reasonably  {E185 request}  additional information  {E39 relating}  to such data, and OntoChem will  {E40 respond}  to such {E185 requests} promptly with any such additional information in its possession or control,  {E41 provided}  that, for clarity, OntoChem will not be  {E42 required}  to  {E43 perform}  any new or additional {E186 research} in order to  {E44 generate}  any such additional information. 2





2.4 Selection of Lead Scaffolds. Within  one year   {E45 following}  {E187 completion} of all {E188 activities} under the Research Plan (the "Selection Deadline"), Anixa, in good faith {E189 consultation} with OntoChem, will have the right to  {E46 select}  up to two hundred (200) Hit Compounds (each, a "Selected Hit Compound"), by  {E47 providing}  OntoChem with written notice of such Selected Hit Compound(s) (the "Selection Notice"), and each  {E190 Selected}  Hit Compound, along with all Variants of such Selected Hit Compound  {E49 referenced}  in the Selection Notice, is hereby  {E50 designated}  as a "Lead Scaffold" under this Agreement.  {E51 Commencing}  upon {E190 selection} of a Selected Hit Compound, Anixa (itself and through its Affiliates and designees) will have sole authority over and control of the further {E191 development}, {E192 manufacture}, and {E193 commercialization} of the corresponding Lead Scaffold and any product candidate or product  {E52 incorporating}  a compound from such Lead Scaffold.  {E53 Following}  the Selection Deadline, Anixa will have no further rights with respect to any Hit Compound that is not a Selected Hit Compound or  {E54 included}  within a Lead Scaffold (each, a "Rejected Hit Compound"),  {E55 provided}  that, during the period of two (2)  years   following  the Selection Deadline, neither OntoChem nor any of its Affiliates will  {E56 use}  or  {E57 disclose}  to any third party any Rejected Hit Compound or any Variant thereof,  {E58 including}  the identity, structure or SAR information of any such compound, for application as anti-viral agents or protease inhibitors, for purposes of  {E59 modulating}  any Target or for {E194 treatment} of virus- {E60 related}  conditions. In case OntoChem  {E242 finds}  a novel and unexpected antiviral {E195 use} of those  {E62 Rejected}   {E63 Hit}  Compounds during this  2-years period , it will  {E244 notify}  Anixa about these {E242 findings} and Anixa has the right of first {E243 negotiation} during a period of  6 months  after this {E244 notification}. If Anixa  {E65 decides}  to not  {E66 license}  those {E196 uses} or compounds for this novel antiviral use, OntoChem is free to  {E67 develop}  those molecules further as its own intellectual property without any further restrictions. 2.5 Subcontractors. OntoChem may  {E68 engage}  one or more subcontractors to  {E69 perform}  its {E197 activities} under the Research Plan with the prior  {E70 written}  approval of Anixa and  {E71 provided}  that, with respect to any such subcontractor, OntoChem will (a) be responsible and liable for the {E198 performance} of such subcontractor and (b)  {E72 enter}  into a  {E73 written}  agreement (i) consistent with terms and conditions of this Agreement,  {E74 including}  with respect to confidentiality and intellectual property, and (ii)  {E75 prohibiting}  such subcontractor from further subcontracting. For clarity, vendors where commercial building blocks or compounds will be  {E76 purchased}  are nor  {E77 regarded}  as subcontractors. 2.6 Target Exclusivity. During the  term  of this Agreement, except in the {E199 performance} of its obligations or {E200 exercise} of its rights under this Agreement, neither OntoChem nor any of its Affiliates will  {E78 discover}  ,  {E79 research}  ,  {E80 develop}  ,  {E81 manufacture}  or  {E82 commercialize}  any compound or product  {E83 directed}  to any Target, either independently or for or in collaboration with a third party ( {E84 including}  the grant of a license to any third party), or have any of the foregoing {E201 activities}  {E85 performed}  on behalf of OntoChem or any of its Affiliates by a third party. For clarity, the foregoing  {E86 includes}  the {E202 screening} ( {E87 including}  via computational methods) of any compound library or virtual compound library against any Target. 2.7 Records. Each Party will  {E88 maintain}  complete and accurate records of all {E245 activities}  {E89 performed}  by or on behalf of such Party under the Research Program and all {E246 Inventions}  {E90 made}  or  {E91 generated}  by or on behalf of such Party in the {E203 performance} of the Research Program. Such records will be in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Each Party will  {E92 provide}  the other Party with the right to  {E93 inspect}  such records, and upon {E204 request} will  {E94 provide}  copies of all such records, to the extent reasonably  {E95 required}  for the {E205 exercise} or {E206 performance} of such other Party's rights or obligations under this Agreement,  {E96 provided}  that any information  {E97 disclosed}  under this Section 2.7 will be subject to the terms and conditions of Section 5. Each Party will  {E98 retain}  such records for at least three (3)  years   following  {E207 expiration} or {E208 termination} of this Agreement or such longer period as may be  {E99 required}  by applicable law or regulation. 3





2.8 Debarment. Each Party hereby  {E100 represents}  and warrants to the other Party that neither it nor any of its Affiliates or personnel has been  {E101 debarred}  under any health care laws or regulations and that, to its knowledge, no {E210 investigations}, {E212 claims} or {E214 proceedings} with respect to {E215 debarment} are  {E102 pending}  or  {E103 threatened}  against such Party or any of its Affiliates or personnel. Neither Party nor any of its Affiliates will  {E104 use}  in any capacity, in connection with the Research Program, any person or entity who has been  {E105 debarred}  . Each Party  {E106 agrees}  and  {E107 undertakes}  to promptly  {E108 notify}  the other Party if such Party or any of its Affiliates or personnel  {E109 becomes}   {E218 debarred}  or {E220 proceedings} have been  {E219 initiated}  against any of them with respect to {E217 debarment}, whether such {E218 debarment} or {E219 initiation} of {E220 proceedings}  {E112 occurs}  during or after the  term  of this Agreement. 3. Financial Terms. 3.1 Research Program Payments. In consideration for OntoChem's {E221 performance} of its {E222 activities} under the Research Plan, Anixa will:

(a)  {E113 pay}  OntoChem 100,002 Euros in six (6) equal installments as  follows  : (i) 16,667 Euros within five (5)  days  after the Effective  Date  ; and (ii) five (5) installments in the amount of 16,667 Euros on each  one-month  anniversary of the Effective  Date  , except that the last such {E223 payment} will be due within thirty (30)  days  after {E224 completion} of all {E225 activities} under the Research Plan; and

(b)  {E114 reimburse}  OntoChem for its out-of-pocket expenses  {E115 incurred}  in  {E116 performing}  the Research Plan on a pass- through basis without mark-up, within thirty (30)  days  after {E226 delivery} of an invoice therefore ( {E117 including}  reasonable  {E118 supporting}  documentation),  {E119 provided}  that Anixa has  {E120 approved}  such expenses in advance and in writing ( including  in regard to the {E227 selection} of specific Hit Compounds to be  {E121 synthesized}  and  {E122 analyzed}  in biological assays). It is  {E123 estimated}  that OntoChem's out-of-pocket expenses under the Research Plan will  {E124 include}  110,000 Euros payable to Tube Pharmaceuticals GmbH as a subcontractor of OntoChem, subject to Section 2.5. (c) High-throughput screening compounds

OntoChem will forward a commercial {E228 proposal} to  {E125 acquire}  these compounds at the sole discretion of Anixa. Both parties will  {E126 agree}  on payment conditions. (d) Extra custom synthesis

OntoChem will forward a commercial {E229 proposal} to have  {E127 synthesized}  these compounds at the sole discretion of Anixa. Both parties will  {E128 agree}  on payment conditions. (e) Biological testing

OntoChem will forward a commercial {E230 proposal} to have biologically  {E129 test}  these compounds at the sole discretion of Anixa. Both parties will  {E130 agree}  on payment conditions. 3.2 Lead Scaffold Payments. For each Lead Scaffold  {E131 selected}  by Anixa, Anixa will  {E132 pay}  OntoChem an  annual  fee of 10,000 U.S. Dollars, payable within thirty (30)  days   following  each anniversary of the date of the Selection Notice, until five (5)  years  after the first commercial {E247 sale} of the first product  {E133 incorporating}  a compound from such Lead Scaffold, subject to Section 4.3 with respect to any Terminated Scaffold (as  {E134 defined}  below). 3.3 Milestone Payment. Anixa will  {E233 pay}  OntoChem a one-time milestone {E233 payment} of 300,000 U.S. Dollars within thirty (30)  days   following  the {E231 dosing} of the first patient in the first human clinical trial for the first product  {E136 incorporating}  a compound from a Lead Scaffold. 4





3.4 Payment Terms. {E232 Payments} to OntoChem will be  {E137 made}  by check or by wire transfer of immediately available funds to such bank account as  {E138 designated}  in writing by OntoChem from time to time. Taxes (and any penalties and interest thereon)  {E139 imposed}  on any {E234 payment}  {E140 made}  by Anixa to OntoChem will be the responsibility of OntoChem. The fees for the respective bank {E235 transfers} will be  {E141 borne}  by Anixa. 3.5 Financial Records. OntoChem will  {E142 maintain}  complete and accurate books and accounting records  {E143 related}  to all out-of-pocket expenses  {E144 incurred}  in  {E145 performing}  the Research Plan. These records will be available for {E236 inspection} during regular business hours upon reasonable {E237 notice} by Anixa, or its duly  {E146 authorized}  representative, at Anixa's expense, for three (3)  years   following  the end of the calendar  year  in which such expenses are  {E147 invoiced}  . If it is  {E148 determined}  that Anixa has  {E238 overpaid}  for any expenses  {E150 passed}  through by OntoChem under this Agreement, OntoChem will promptly  {E151 reimburse}  Anixa for the amount of such {E238 overpayment} and, if such {E239 overpayment}  {E152 represents}  more than five percent (5%) of the corresponding amount due, OntoChem will  {E153 pay}  Anixa's reasonable fees and expenses  {E154 incurred}  in connection with such {E240 inspection}. 4.  Term  and Termination. 4.1  Term  . Unless earlier  {E155 terminated}  in accordance with Section 4.2 or 4.3, this Agreement will be in effect from the Effective  Date  until {E241 completion} of the Research Program. 4.2 Termination by Anixa. This Agreement may be  {E156 terminated}  by Anixa, without cause, upon at least thirty (30)  days   {E157 written}  notice to OntoChem. 4.3 Termination of Lead Scaffolds.




